Skip to main content
SpringerLink
Log in

Cost considerations in using filgrastim to prevent antineoplastic therapy-induced neutropenia

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Faulds D. Using filgrastim efficiently [correspondence]. PharmacoEconomics 1996 May; 9(5): 467–8

    Article  Google Scholar 

  2. Frampton JE, Faulds D. Filgrastim: a reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia. PharmacoEconomics 1996 Jan; 9(1): 76–96

    Article  PubMed  CAS  Google Scholar 

  3. Uyl-de Groot CA, Huijgens PC, Rutten FH. Colony-stimulating factors and peripheral blood progenitor cell transplantation: benefits and costs. PharmacoEconomics 1996 Jul; 10(1): 23–35

    Article  PubMed  CAS  Google Scholar 

  4. Dranitsaris G. Using filgrastim efficiently [correspondence]. PharmacoEconomics 1996 May; 9(5): 466–7

    Article  PubMed  CAS  Google Scholar 

  5. Frampton JE, Lee CR, Faulds D. Filgrastim: a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1994 Nov; 48(5): 731–60

    Article  PubMed  CAS  Google Scholar 

  6. Glaspy JA, Bleecker G, Crawford J, et al. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer A 1993 Dec; 29A Suppl. 7: 23–30

    Article  Google Scholar 

  7. Lyman GH, Lyman CG, Sanderson RA, et al. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993 Mar 17; 85: 488–93

    Article  PubMed  CAS  Google Scholar 

  8. Nichols CR, Fox EP, Roth BJ, et al. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 1994; 12: 1245–50

    PubMed  CAS  Google Scholar 

  9. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994 Nov; 12(11): 2471–2508

    Google Scholar 

  10. Faucher C, le Corroller AG, Blaise D, et al. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 1994 Dec; 14: 895–901

    PubMed  CAS  Google Scholar 

  11. Uyl-de Groot CA, Richel DJ, Rutten FFH. Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation. Eur J Cancer A 1994 Nov; 30A: 1631–5

    Article  PubMed  CAS  Google Scholar 

  12. Pettengell R, Gurney J, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomised controlled trial. Blood 1992; 80: 1430–6

    PubMed  CAS  Google Scholar 

  13. Filgrastim — human granulocyte-colony stimulating factor. Drug Ther Bull 1993 Apr 26; 31: 33–5

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cost considerations in using filgrastim to prevent antineoplastic therapy-induced neutropenia. Drugs Ther. Perspect 8, 13–16 (1996). https://doi.org/10.2165/00042310-199608030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199608030-00005

Search

Navigation